Aug 42026 AdvanTIG302: Ociperlimab Plus Tislelizumab Does Not Improve Survival in PDL1High NSCLC AdvanTIG-302 found no survival benefit from ociperlimab plus tislelizumab over pembrolizumab in PD-L1–high advanced NSCLC.
